Standard BioTools (Nasdaq:LAB) - Aandelenkoers, Nieuws & Analyse

LAB Overzicht aandelen

LAB fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 14.71% per jaar groeien

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Volatiele aandelenkoers in de afgelopen 3 maanden

Standard BioTools Inc. Concurrenten

Adaptive Biotechnologies

NasdaqGS:ADPT

US$875.1m

Quanterix

NasdaqGM:QTRX

US$582.2m

Mesa Laboratories

NasdaqGS:MLAB

US$610.5m

Cytek Biosciences

NasdaqGS:CTKB

US$906.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Standard BioTools
Historische aandelenkoersen
Huidige aandelenkoers	US$1.84
52 Week Hoogtepunt	US$3.04
52 Week Laag	US$1.21
Bèta	1.57
11 maand verandering	-2.65%
3 maanden verandering	2.22%
1 Jaar Verandering	-16.36%
33 jaar verandering	-61.18%
5 jaar verandering	-20.00%
Verandering sinds IPO	-86.88%

Recent nieuws en updates

Standard BioTools (NASDAQ:LAB) Has Debt But No Earnings; Should You Worry?

Oct 26

Market Participants Recognise Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 33% Higher

Sep 14

Recent updates

Standard BioTools (NASDAQ:LAB) Has Debt But No Earnings; Should You Worry?

Oct 26

Market Participants Recognise Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 33% Higher

Sep 14

Newsflash: Standard BioTools Inc. (NASDAQ:LAB) Analysts Have Been Trimming Their Revenue Forecasts

Aug 05

Revenues Tell The Story For Standard BioTools Inc. (NASDAQ:LAB) As Its Stock Soars 42%

Jul 26

Rendement voor aandeelhouders

	LAB	US Life Sciences	US Markt
7D	-18.6%	-2.7%	1.0%
1Y	-16.4%	11.8%	33.1%

Rendement versus industrie: LAB presteerde slechter dan de US Life Sciences -sector, die het afgelopen jaar een rendement van 13.9 % opleverde.

Rendement versus markt: LAB presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 33.2 % opleverde.

Prijsvolatiliteit

Is LAB's price volatile compared to industry and market?
LAB volatility
LAB Average Weekly Movement	10.1%
Life Sciences Industry Average Movement	8.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.6%
10% least volatile stocks in US Market	3.0%

Stabiele aandelenkoers: De aandelenkoers van LAB is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van LAB is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1999	537	Michael Egholm	www.standardbio.com

Standard BioTools Inc. levert samen met zijn dochterondernemingen instrumenten, verbruiksartikelen, reagentia en softwarediensten voor onderzoekers en klinische laboratoria in Noord- en Zuid-Amerika, Europa, het Midden-Oosten, Afrika en Azië-Pacific. Het bedrijf is actief in twee segmenten: Proteomics en Genomics. Het bedrijf biedt analytische systemen, zoals CyTOF XT System, een CyTOF XT massa-cytometriesysteem dat geautomatiseerde hoog-parameter single-cell analyse uitvoert met behulp van antilichamen geconjugeerd aan metaalisotopen; en Hyperion XTi imaging system, een ruimtelijk biologisch instrument.

Standard BioTools Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Standard BioTools zich tot de beurswaarde?
LAB fundamentele statistieken
Marktkapitalisatie	US$763.13m
Inkomsten(TTM)	-US$170.60m
Inkomsten(TTM)	US$155.90m

4.4x

P/S-verhouding

-4.0x

Koers/Winstverhouding

Is LAB overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
LAB resultatenrekening (TTM)
Inkomsten	US$155.90m
Kosten van inkomsten	US$80.19m
Brutowinst	US$75.71m
Overige uitgaven	US$246.32m
Inkomsten	-US$170.60m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.46
Brutomarge	48.57%
Nettowinstmarge	-109.43%
Schuld/Eigen Vermogen Verhouding	11.3%

Hoe presteerde LAB op de lange termijn?

Bekijk historische prestaties en vergelijking

LAB Overzicht aandelen

Beloningen

Risicoanalyse

Standard BioTools Inc. Concurrenten

NasdaqGS:ADPT

US$875.1m

NasdaqGM:QTRX

US$582.2m

NasdaqGS:MLAB

US$610.5m

NasdaqGS:CTKB

US$906.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Standard BioTools Inc. Announces the Appointment of Alex Kim as Chief Financial Officer, Effective November 11, 2024

Standard BioTools Inc. Reiterates Revenue Guidance for Full Year 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Standard BioTools (NASDAQ:LAB) Has Debt But No Earnings; Should You Worry?

Standard BioTools Inc. to Report Q3, 2024 Results on Oct 30, 2024

Market Participants Recognise Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 33% Higher

Recent updates

Standard BioTools Inc. Announces the Appointment of Alex Kim as Chief Financial Officer, Effective November 11, 2024

Standard BioTools Inc. Reiterates Revenue Guidance for Full Year 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Standard BioTools (NASDAQ:LAB) Has Debt But No Earnings; Should You Worry?

Standard BioTools Inc. to Report Q3, 2024 Results on Oct 30, 2024

Market Participants Recognise Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 33% Higher

Consensus revenue estimates decrease by 15%

Newsflash: Standard BioTools Inc. (NASDAQ:LAB) Analysts Have Been Trimming Their Revenue Forecasts

No longer forecast to breakeven

Standard BioTools Inc. Revises Revenue Guidance for the Full Year 2024

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Standard BioTools Inc. Announces Chief Financial Officer Changes

Revenues Tell The Story For Standard BioTools Inc. (NASDAQ:LAB) As Its Stock Soars 42%

Forecast to breakeven in 2026

High number of new and inexperienced directors

Standard BioTools Inc. to Report Q2, 2024 Results on Jul 31, 2024

Standard BioTools Inc., Annual General Meeting, Jun 27, 2024

Standard BioTools Inc. Reaffirms Revenue Guidance for the Fiscal Year 2024

Standard BioTools Inc. to Report Q1, 2024 Results on May 08, 2024

Standard BioTools Inc. Announces Operational Restructuring Plan

Now 21% undervalued

Standard BioTools Inc. Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the Boundaries of Tissue Imaging

Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)?

Consensus EPS estimates upgraded to US$0.43 loss

Chief Strategy Officer notifies of intention to sell stock

Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)

Forecast to breakeven in 2026

Standard BioTools Inc. Provides Revenue Guidance for the Full Year 2024

New major risk - Financial position

Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable

Standard BioTools Inc. to Report Q4, 2023 Results on Feb 28, 2024

Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?

New major risk - Revenue and earnings growth

Standard Biotools Inc. Provides Revenue Guidance for the Fourth Quarter and full year 2023

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Standard BioTools Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is Standard BioTools (NASDAQ:LAB) A Risky Investment?

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Standard BioTools Inc. to Report Q2, 2023 Results on Aug 08, 2023

High number of new directors

Senior VP & CFO recently bought US$194k worth of stock

Standard BioTools Inc. Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System

Standard BioTools Inc. Appoints Jeffrey Black as Chief Financial Officer

First quarter 2023 earnings released: US$0.21 loss per share (vs US$0.99 loss in 1Q 2022)

Standard BioTools Inc. Announces Retirement of Gerhard Burbach as Member of the Board of Directors

Chief Financial Officer exercised options and sold US$58k worth of stock

Standard BioTools Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$2.43 loss per share (vs US$0.78 loss in FY 2021)

Standard BioTools Inc. to Report Q4, 2022 Results on Feb 14, 2023

Standard Biotools Inc. Appoints Betsy Jensen as Chief Human Resources Officer

Standard BioTools Inc. (NasdaqGS:LAB) announces an Equity Buyback for $20 million worth of its shares.

Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021)

Standard BioTools Inc. to Report Q3, 2022 Results on Nov 08, 2022

Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform

Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.23 loss in 2Q 2021)

Standard BioTools Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2022